Oncowitan logo (white)
  • About us
  • Our offer
    • Scientific writing & evaluation
    • Pharma projects
    • CDMO support
  • News
    • CDMO
    • Publications
  • [Gallery]

Gallery

News-Publications

New publication: Modulation of the TIM-3/Gal-9 immune checkpoint to control neglected tropical diseases.

(more…)

By Christian Bailly, 2 years21 December 2022 ago
Gallery

Algesal® (nopoxamine and diethylamine salicylate), from Laboratoires Latema (Paris), 1971

(more…)

By Christian Bailly, 2 years10 December 2022 ago
Gallery

Abriscor® (ascorbic acid), from Laboratoires Synthelabo (Paris), 1971

(more…)

By Christian Bailly, 2 years19 November 2022 ago
News-Publications

New publication: The interaction of plant alkaloids with the enzyme Sirtuin-1 analyzed by molecular modeling.

(more…)

By Christian Bailly, 2 years19 November 2022 ago
Gallery

Aminox®, from Laboratoires Fournier (Dijon), 1971

(more…)

By Christian Bailly, 2 years13 November 2022 ago
Gallery

Vulvacycline® (tetracycline, dihydronovobiocin), from Laboratoires Lepetit (Suresnes), 1971

(more…)

By Christian Bailly, 3 years24 October 2022 ago
News-Publications

New publication: The bioactive products isolated from the Chinese medicinal plant yingzhao (Artabotrys hexapetalus) and their mechanism of action.

(more…)

By Christian Bailly, 3 years15 October 2022 ago
Gallery

Rifocine® (Rifamycin SV), from Laboratoires Lepetit (Suresnes, F), 1971

(more…)

By Christian Bailly, 3 years6 October 2022 ago
Gallery

Acidrine® (nopoxamine lauryl sulfate), from Laboratoires Latéma (Paris), 1971

(more…)

By Christian Bailly, 3 years24 September 2022 ago
News-Publications

New publication: A docking study to guide the design of compounds targeting the ubiquitin-specific protease 4 (USP4).

(more…)

By Christian Bailly, 3 years24 September 2022 ago

Posts navigation

Previous 1 … 8 9 10 … 25 Next
Search
  • Our partners
  • Contact
  • Legal notice
Hestia | Developed by ThemeIsle
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK